Roche, Spark Therapeutics Acquisition Delayed Under Regulatory Review

Article

Roche has extended its offering period for the purchase of Spark to provide US and UK regulatory authorities with additional time to complete their review of the acquisition.

On Sept. 3, 2019, Roche and Spark Therapeutics announced that Roche has extended the offering period of its previously announced tender offer to purchase all of the outstanding shares of Spark common stock for $114.50 per share. The offer was previously scheduled to expire at 5:00 p.m., New York City time, on Tuesday, Sept. 3, 2019. This has been extended until 5:00 p.m., New York City time, on Tuesday, Oct. 1, 2019.

The offering was extended to provide additional time for the US Federal Trade Commission (FTC) and the UK Competition and Markets Authority (CMA) to complete their previously disclosed reviews of Roche’s pending acquisition of Spark. The parties remain committed to the transaction and are working cooperatively and expeditiously with the FTC and the CMA, Roche reports.

Closing of the tender offer is conditioned upon customary closing conditions.

Source: Roche

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Recent Videos
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Preeya Beczek, managing director and co-founder of Beczek.COM, chats about industry trends from 2024 and which of those might impact the industry in 2025, including the big trend of AI.
Related Content
© 2025 MJH Life Sciences

All rights reserved.